NEW YORK & FRANKLIN, Tennessee–(BUSINESS WIRE). Combined with Massive Bio’s ability to provide patients with personalized clinical trial options, the two companies working together will provide early detection and precise treatment options, further advancing the clinical management of cancer.
Today, clinical care teams have limited scope to review important diagnoses such as patient pathology reports. Each report takes one to two minutes to read, delaying study opportunities for patients with an urgent, life-changing health situation. Azra AI’s technology, used in over 200 hospitals including HCA Healthcare, reads pathology reports in a split second, allowing physicians to immediately focus on the approximately 10 percent positive pathology reports to treat patients earlier and give them the best chance of survival.
“Our mission is to bring hope and empower cancer patients by helping them find their best treatment options, which often requires urgent access to trials,” said Selin Kurnaz, co-founder and CEO of Massive Bio. “We are excited to partner with Azra AI and expand our growing ecosystem of like-minded leaders who are just as passionate about transforming cancer clinical trials as we are. This is a monumental moment when advanced technology intersects with medical science to transform lives in a meaningful way.”
While Azra AI focuses on cancer detection, Massive Bio’s platform provides cancer patients with relevant clinical trials powered by AI, empowering patients to find treatment options faster and life science companies empowering a conduct broader, more comprehensive, population-based recruitment instead of traditional websites – specific recruitment. The companies’ collaboration has the potential to have an immediate impact on thousands of cancer patients – Azra AI’s technology touches nearly one in 10 cancer patients in the US, while Massive Bio recently announced the enrollment of more than 100,000 patients in its trial matching platform gave.
By using AI technology in cancer detection and study matching, clinical care teams can improve healthcare access and equity by eliminating unconscious bias or human error that can prevent successful patient enrollment. Additionally, healthcare teams can automatically operationalize the volumes of data collected to improve the patient experience in ways they could not previously do.
“We are very interested in working with Massive Bio to bridge these two parts of the cancer journey,” said Azra AI founder and CEO Chris Cashwell. “We can revolutionize the clinical trial process by automating the early identification of potential patients using artificial intelligence. We comb through millions of pathology reports and identify cancers faster. The data sent to Massive Bio’s platform closes the loop to provide this patient with the best treatment options for their cancer. This allows our clinical teams to focus on cancer care and leverage AI to deliver the best patient experience.”
To learn more about how Massive Bio and Azra AI are working together to improve clinical cancer research, listen to Arturo Loaiza-Bonilla, MD, Massive Bio Co-Founder and Chief Medical Officer, at HLTH 2022 in Las Vegas on Tuesday, November 15 at 4:20 p.m. on the gallery stage.
About Azra AI:
Azra AI uses proprietary artificial intelligence software to read millions of unstructured data sets and identify at-risk patients in need of follow-up, leading to more equitable health outcomes, increased patient retention and reduced burden on clinical staff. This revolutionary technology, used in hospitals and cancer centers across the country, automates the identification and navigation process, positively impacting clinical, financial and operational outcomes. Azra AI is headquartered in Franklin, TN and has over 200 hospital customers including HCA Healthcare. Learn more about Azra AI and follow us at @Azra_AI_Health.
About MassiveBio:
Massive Bio empowers cancer patients to find their best treatment options by providing convenient access and enrollment services to oncology clinical trials worldwide, powered by advanced artificial intelligence. Founded on the belief that all people should have equal access to cutting-edge therapies, Massive Bio combines its best-in-class AI platform with expertise in genomics, engineering and data analysis to remove the many barriers to cancer patient enrollment and participation in clinical trials. Headquartered in New York, Massive Bio is a privately held company with operations in 12 countries.
